Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 986 in Healthy Subjects and Heart Failure Patients
NCT03276728Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, randomised, double-blind trial of azelaprag in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (8 arms), sponsored by Amgen. Primary endpoint: Participants With Treatment Emergent Adverse Events. Started Aug 2016; status: terminated.
02
Drugs
azelaprag
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03276728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276728.